Christopher Gibson - Jan 31, 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Executive Officer, Director
Signature
/s/ Nathan Hatfield, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Jan 31, 2022
Transactions value $
-$232,964
Form type
4
Date filed
2/2/2022, 07:09 PM
Previous filing
Jan 14, 2022
Next filing
Feb 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Conversion of derivative security $0 +19.9K +84.61% $0.00 43.3K Jan 31, 2022 Direct F1
transaction RXRX Class A Common Stock Sale -$233K -19.9K -45.83% $11.73 23.5K Jan 31, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Class B Common Stock Conversion of derivative security $0 -19.9K -0.26% $0.00 7.76M Jan 31, 2022 Class A Common Stock 19.9K $0.00 Direct F4
holding RXRX Stock Option (Right to Buy) 1.47M Jan 31, 2022 Class A Common Stock 1.47M $2.47 Direct F5
holding RXRX Class B Common Stock 550K Jan 31, 2022 Class A Common Stock 550K $0.00 by LAHWRAN-3 LLC F4, F6
holding RXRX Class B Common Stock 550K Jan 31, 2022 Class A Common Stock 550K $0.00 by LAHWRAN-4 LLC F4, F7
holding RXRX Class B Common Stock 147K Jan 31, 2022 Class A Common Stock 147K $0.00 by Gibson Family Trust F4, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the conversion of Class B Common Stock into Class A Common Stock.
F2 Shares were sold by a lender to the Reporting Person to satisfy a margin call related to a loan in which the shares served as collateral.
F3 This transaction was executed in multiple trades at prices ranging from $11.43 to $11.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F5 The option, originally for 1,500,000 shares, of which 28,646 shares have been exercised, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F6 The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
F7 The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
F8 The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.